Ferreira JP, et al. - Researchers examined the links between 6-minute walk test (6MWT) distance and the composite of heart failure (HF) hospitalization and/or death by using Cox proportional hazards models in BIOSTAT-CHF (BIOlogy Study to TAilored Treatment in Chronic Heart Failure) enrolling 1714 HF patients who underwent 6MWT at baseline and 1520 who had 6MWT at 9 months. Participants were followed-up for a median duration of 21 months. A shorter 6MWT distance was independently predicted by older age, female sex, higher heart rate, New York Heart Association class III/IV, orthopnoea, ischaemic heart disease, a previous stroke, current malignancy, and higher N-terminal pro-B-type natriuretic peptide. A worse prognosis was evident in relation to both the 6MWT distance at baseline and a decline in walking distance, however, both of these did not improve the prognostic models. Treatment up-titration had no modifying impact on 6MWT distance. Also, 6MWT distance may have limited use for evaluating the benefits of pharmacologic treatment up-titration.